Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | December 10, 2020 | December 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date December 10, 2020 · Filed December 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,933,429 |
Reported balance
After 2020-12-10 transaction · row 1
1 source rowRow 1 · 2020-12-10 · Grant · Acquired 432,432 · Balance 3,933,429 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2020 Filed Dec 14, 2020 21:21 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 432,432 | $3.70 | $1,599,998.40 |
DisclosureSEC source: 0001209191-20-063214 · doc4.xml · nonDerivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,933,429 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001209191-20-037558 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 16, 2020 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:21 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 677,419 | $4.65 | $3,149,998.35 |
DisclosureSEC source: 0001209191-19-043479 · doc4.xml · nonDerivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500,997 Read SEC document |
| June 14, 2019 Filed Jul 12, 2019 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GiftCommon Stock | 562,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041954 · doc4.xml · nonDerivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823,578 Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:11 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-19-037117 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This option was granted on June 13, 2019 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 18:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,300 | $32.20 | $106,258.02 |
DisclosureSEC source: 0000899243-19-001270 · doc4.xml · nonDerivative · entry 2 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,386,293 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 18:07 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 1,700 | $31.60 | $53,723.74 |
DisclosureSEC source: 0000899243-19-001270 · doc4.xml · nonDerivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,389,593 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $32.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 5,000 | $30.08 | $150,406.50 |
DisclosureSEC source: 0000899243-19-000742 · doc4.xml · nonDerivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,391,293 F1 · shares: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,165 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0000899243-18-031202 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,165 Underlying: Common Stock · 8,165 shares Expires 2028-12-13 F1 · derivative.exercise_date: This option was granted on December 13, 2018 and vests in full on the earlier to occur of July 25, 2019 and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:54 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,835 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0000899243-18-020709 · doc4.xml · derivative · entry 1 Arnold Matthew Bennett · CIK 0001727991 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,835 Underlying: Common Stock · 1,835 shares Expires 2028-07-25 F1 · derivative.exercise_date: This option was granted on July 25, 2018 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's first annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.